Search clinical trials for: Tislelizumab Sitravatinib

Total 462 results

BeiGene

Completed

A Study to Investigate Sitravatinib as Monotherapy and in Combination With Tislelizumab in Participants With Unresectable Locally Advanced or Metastatic Hepatocellular Carcinoma (HCC) or Gastric/Gastroesophageal Junction Cancer (GC/GEJC)

Carcinoma, Hepatocellular | Gastric/Gastroesophageal Junction Cancer

China
Peking University Cancer Hospital & Institute

Recruiting

Sitravatinib With or Without Tislelizumab in Patients With Unresectable or Metastatic Melanoma

Melanoma

China
BeiGene

Withdrawn

Efficacy and Safety of Sitravatinib Plus Tislelizumab or Placebo Plus Tislelizumab Versus Placebo as Adjuvant Treatment in Participants With Hepatocellular Carcinoma

Hepatocellular Carcinoma
BeiGene

Completed

A Phase 1b Study to Assess Sitravatinib in Combination With Tislelizumab in Patients With Advanced Solid Tumors.

Advanced Solid Tumors

China, Australia
Anhui Provincial Hospital
Henan Cancer Hospital; First Affiliated Hospital Xi'an Jiaotong University; First...

Recruiting

A Study to Evaluate Tislelizumab Combined With Sitravatinib as Adjuvant Therapy in Participants With HCC at High Risk of Recurrence After Curative Resection

Hepatocellular Carcinoma

China
Fudan University

Terminated

Tislelizumab Combined With Sitravatinib as Consolidation Treatment Following Concurrent Chemoradiation in Patients With Locally Advanced, Unresectable NSCLC

Non-small Cell Lung Cancer

China
Zhejiang Cancer Hospital

Active, not recruiting

A Study to Investigate the Efficacy and Safety of Tislelizumab Combined With Sitravatinib as Maintenance Therapy for ES-SCLC

Lung Cancer, Small Cell

China
Seoul National University Hospital
BeiGene

Active, not recruiting

Phase II Study of Sitravatinib in Combination With Tislelizumab in Patients With Advanced Biliary Tract Cancer (BTC-BGB)

Advanced Biliary Tract Cancer

Korea, Republic of
Grupo Español Multidisciplinar de Melanoma
Mirati Therapeutics Inc.; BeiGene

Active, not recruiting

Sitravatinib and Tislelizumab in Patients With Metastatic Uveal Melanoma With Liver Metastases. (SITISVEAL)

Uveal Melanoma

Spain
Australia New Zealand Gynaecological Oncology Group
BeiGene

Withdrawn

Tislelizumab in Combination With Sitravatinib for Recurrent/Metastatic Cervical Cancer After Platinum-Based Chemotherapy (ITTACC)

Metastatic Cervical Cancer
Mirati Therapeutics Inc.

Completed

A Study to Evaluate the Effect of Mild, Moderate, and Severe Hepatic Impairment on Pharmacokinetics of Sitravatinib

Hepatic Impairment

United States
BeiGene

Completed

Relative Bioavailability of Two Different Capsule Formulations of Sitravatinib in Healthy Adults

Tumor

Australia
BeiGene

Terminated

Tislelizumab in Combination With Sitravatinib in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Non-Small Cell Lung Cancer (NSCLC)

China, Australia
Sun Yat-sen University

Recruiting

Neoadjuvant Tisleizumab(BGB-A317) for dMMR/MSI-H Non-late Stage CRC Patients Before Surgery

Immunotherapy | DMMR Colorectal Cancer | Anti PD-1

China
Mirati Therapeutics Inc.

Completed

A Study to Explore the Effect of Food Before a Single Dose of Sitravatinib

Healthy Adults

United States
C. Kent Osborne, MD
Mirati Therapeutics Inc.

Withdrawn

Sitravatinib in Metastatic Breast Cancer

Breast Neoplasms | Triple Negative Breast Cancer | Breast Cancer Stage IV | Breast Cancer Metastatic

United States
Matthew Ingham
Mirati Therapeutics Inc.

Active, not recruiting

Sitravatinib in Advanced Liposarcoma and Other Soft Tissue Sarcomas

Liposarcoma | Metastatic Liposarcoma

United States
BeiGene

Terminated

Study To Investigate the Efficacy and Safety of Sitravatinib in Combination With Tislelizumab in Participants With Esophageal Squamous Cell Carcinoma

Esophageal Squamous Cell Carcinoma

China
Mirati Therapeutics Inc.

Completed

Phase 1/1b Study of MGCD516 in Patients With Advanced Cancer

Advanced Cancer

Korea, Republic of, United States
Peking University Cancer Hospital & Institute

Recruiting

Tislelizumab Consolidation Therapy After Radiotherapy or Sequential Chemoradiation in Locally Advanced NSCLC Patients

Non-small Cell Lung Cancer | Consolidation Immunotherapy | Radiotherapy or Sequential Chemoradiation

China
Jiangsu Yahong Meditech Co., Ltd aka Asieris

Recruiting

A Study to Evaluate the Safety and Efficacy of Oral APL-1202 in Combination With Tislelizumab Compared to Tislelizumab Alone as Neoadjuvant Therapy in Patients With Muscle Invasive Bladder Cancer (ANTICIPATE)

Muscle Invasive Bladder Cancer

United States, China
Fudan University

Active, not recruiting

Tislelizumab in the Systematic Treatment of Advanced Hepatocellular Carcinoma

Hepatocellular Carcinoma

China
Henan Cancer Hospital

Not yet recruiting

Study of Donafenib Combined With Tislelizumab in the Adjuvant Treatment of Primary HCC With High Risk of Recurrence

Hepatocellular Carcinoma
Shanghai Gopherwood Biotech Co., Ltd.

Recruiting

Phase I/IIa Study of BR790 in Combination With Tislelizumab in Adult Subjects With Advanced Solid Tumors

Advanced Solid Tumor

China
GeneScience Pharmaceuticals Co., Ltd.

Recruiting

Genakumab Alone and in Combination With Tislelizumab in Patients With Advanced Malignant Solid Tumors

Malignant Solid Tumors

China
Fudan University

Recruiting

Oncolytic Virotherapy Plus PD-1 Inhibitor for Patients With Refractory Malignant Ascites

Refractory Malignant Ascites

China
Peter MacCallum Cancer Centre, Australia

Recruiting

A Trial of Pamiparib With Tislelizumab in Patients With Advanced Tumours With Homologous Recombination Repair Defects (IMPARP-HRD)

Cancer

Australia
Peking University

Recruiting

Tislelizumab Plus Anlotinib for Immunotherapy Resistant Gastrointestinal Cancer

Gastric Cancer | Colo-rectal Cancer

China
Fudan University

Not yet recruiting

Tislelizumab in Combination With Eribulin for Patients With Metastatic Previously heaviLy-treAted TriplE-negative Breast Cancer：A Prospective Multiple-center Phase II Study (TEMPLATE)

Triple Negative Breast Cancer

China
Fudan University

Active, not recruiting

A Phase II Study to Explore the Safety, Tolerability, and Preliminary Antitumor Activity of Sitravatinib Plus Tislelizumab or Combination With Nab-paclitaxel in Patients With Locally Recurrent or Metastatic Triple Negative Breast Cancer (TNBC) (SPARK)

Metastatic Breast Cancer

China
Sun Yat-sen University

Recruiting

Tislelizumab or Tislelizumab Combined With Lenvatinib Neo-adjuvant Treatment for Resectable RHCC (TALENT)

Recurrent Hepatocellular Carcinoma

China
XIANG YANQUN

Recruiting

Tislelizumab in Combination With GP or TPC Regimen for the Treatment of Nasopharyngeal Carcinoma With Bone Metastasis.

Nasopharyngeal Carcinoma

China
University College, London
BeiGene

Not yet recruiting

Response Adapted Incorporation of Tislelizumab Into the Front-line Treatment of Older Patients With Hodgkin lYmphoma (RATiFY)

Hodgkin Lymphoma
Fudan University

Recruiting

Tislelizumab Plus GX Versus Tislelizumab Plus GP in the Treatment of R/M NPC

Nasopharyngeal Carcinoma

China
Huihua Xiong

Not yet recruiting

Surufatinib Combined With Tislelizumab in the Second-line and Further Treatment of Triple-negative Breast Cancer

Metastatic Triple-negative Breast Cancer

China
Yonsei University

Not yet recruiting

Study to Evaluate the Safety and Efficacy of Tislelizumab in Combination With Zanidatamab as a 2nd Line in HER2-Positive Advanced Gastric Cancer in K-Umbrella Trial

HER2-positive Gastric Cancer

Korea, Republic of
Shanghai Zhongshan Hospital

Not yet recruiting

Tislelizumab Combined With IMRT Neoadjuvant Treatment for Resectable Hepatocellular Carcinoma With PVTT

Hepatocellular Carcinoma With Portal Vein Tumor Thrombus

China
Peking Union Medical College Hospital
Henan Cancer Hospital; Qilu Hospital of Shandong University; Beijing Tongren... and other collaborators

Recruiting

Phase II Study of Orelabrutinib Combined With PD-1 Inhibitor in Relapsed/Refractory Primary Central Nervous System Lymphoma

Primary Central Nervous System Lymphoma

China
BeiGene

Completed

Study of Tislelizumab in Participants With Locally Advanced or Metastatic Urothelial Bladder Cancer

Locally Advanced or Metastatic Urothelial Bladder Cancer

Korea, Republic of, China
BeiGene

Completed

Study of BGB-A317 in Participants With Relapsed or Refractory Mature T- and NK-cell Neoplasms

Cutaneous T-cell Lymphoma | Anaplastic Large Cell Lymphoma | Angioimmunoblastic T-cell Lymphoma | Adult Nasal Type Extranodal NK/T-cell Lymphoma | Anaplastic Large Cell Lymphoma, ALK-Positive | Extranodal NK/T-cell Lymphoma, Nasal Type | Peripheral T Cell Lymphoma | Extranodal NK/T-cell Lymphoma | Peripheral... and other conditions

China, Taiwan, Germany, France, Canada, Italy
BeiGene

Completed

A Study of Tislelizumab as Monotherapy in Relapsed or Refractory Classical Hodgkin Lymphoma

Classical Hodgkin Lymphoma

China
Peking Union Medical College Hospital

Not yet recruiting

Nimotuzumab Plus Tislelizumab for Recurrent and Metastatic Cervical Cancer

Cervical Cancer
Peking Union Medical College Hospital

Recruiting

RC48 Combined With Tislelizumab for Second-line Treatment of HER2 Expression in Recurrent Cervical Cancer

Cervical Cancer Recurrent

China
Hebei Medical University Fourth Hospital

Recruiting

Efficacy and Safety of Tislelizumab for Lung Adenocarcinoma With Asymptomatic Brain Metastatic

Lung Adenocarcinoma

China
Ming Zhao

Recruiting

Ablation Plus Tislelizumab Versus Ablation Alone for Intrahepatic Recurrent Early Stage HCC

Recurrent Hepatocellular Carcinoma

China
China Medical University, China

Not yet recruiting

Chemotherapy Sequential Tislelizumab After Radical Resection in Patients With dMMR/MSI-H or POLE/POLD1 Mutations

Colorectal Adenocarcinoma | Gastric

China
BeiGene

Recruiting

Tislelizumab (Anti-Programmed Cell Death Protein-1 (PD-1) Antibody) in MSI-H or dMMR Solid Tumors

MSI-H/dMMR Solid Tumors

China
Tianjin Medical University Cancer Institute and...

Recruiting

Radiotherapy With Tislelizumab in Patients With Recurrent Head & Neck Cancer

Head and Neck Cancer

China
Quanli Gao

Not yet recruiting

L-TIL Plus Tislelizumab as First-line Treatment in Advanced Malignant Melanoma

Malignant Melanoma
Sun Yat-sen University

Recruiting

Chidamide With Immunotherapy for Patients With Locally Advanced or Metastatic Urothelial Carcinoma

Bladder Cancer Stage IV

China

3

Subscribe